MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer

Zhou, Lianming; Dong, Jian; Huang, Gengwen; Sun, Zhengwei; Wu, Jiang

doi:10.1590/1414-431x20175891

Cited by 34 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, similar to our results, miR-187 has been associated with breast cancer progression and worse survival (5,48). Reports on the role of miR-143 in breast cancer are mixed (49), with several laboratory studies indicating a tumorsuppressive effect (50)(51)(52)(53)(54), while others suggest tumorigenic effects (55). To our knowledge, our finding that miR-143 is associated with worse prognosis in long-term breast cancer survival after adjusting for clinical factors and PAM50 subtypes is novel and has not been reported previously.…”

Section: Discussionsupporting

confidence: 88%

miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study

Davies

Vickery

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: There is substantial variation in breast cancer survival rates, even among patients with similar clinical and genomic profiles. New biomarkers are needed to improve risk stratification and inform treatment options. Our aim was to identify novel miRNAs associated with breast cancer survival and quantify their prognostic value after adjusting for established clinical factors and genomic markers. Methods: Using the Women's Healthy Eating and Living (WHEL) breast cancer cohort with >15 years of follow-up and archived tumor specimens, we assayed PAM50 mRNAs and 25 miRNAs using the Nanostring nCounter platform. Results: We obtained high-quality reads on 1,253 samples (75% of available specimens) and used an existing researchuse algorithm to ascertain PAM50 subtypes and risk scores (ROR-PT). We identified miRNAs significantly associated with breast cancer outcomes and then tested these in independent TCGA samples. miRNAs that were also prognostic in TCGA samples were further evaluated in multiple regression Cox models. We also used penalized regression for unbiased discovery. Conclusions: Two miRNAs, 210 and 29c, were associated with breast cancer outcomes in the WHEL and TCGA studies and further improved risk stratification within PAM50 risk groups: 10-year survival was 62% in the node-negative high miR-210-high ROR-PT group versus 75% in the low miR-210high ROR-PT group. Similar results were obtained for miR-29c. We identified three additional miRNAs, 187-3p, 143-3p, and 205-5p, via penalized regression. Impact: Our findings suggest that miRNAs might be prognostic for long-term breast cancer survival and might improve risk stratification. Further research to incorporate miRNAs into existing clinicogenomic signatures is needed.

show abstract

Section: Discussionsupporting

confidence: 88%

miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study

Davies

Vickery

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Hsa-miR-143 was also found significantly upregulated specifically to the nodular subtype (Fig. 2B ) and known for its tumour suppressive action 22 . It is likely to be acting through suppression of BCL2 , which is also targeted by the aforementioned hsa-miR-16 and -34a, helping to prevent cancer progression.…”

Section: Resultsmentioning

confidence: 89%

MicroRNA and transcriptome analysis in periocular Sebaceous Gland Carcinoma

Bladen

Wang

Sangaralingam

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Sebaceous gland carcinoma (SGC) is a rare, but life-threatening condition with a predilection for the periocular region. Eyelid SGC can be broadly categorised into two subtypes, namely either nodular or pagetoid with the latter being more aggressive and requiring radical excision to save life. We have identified key altered microRNAs (miRNA) involved in SGC shared by both subtypes, hsa-miR-34a-5p and hsa-miR-16-5p. However, their gene targets BCL2 and MYC were differentially expressed with both overexpressed in pagetoid but unchanged in nodular suggesting different modes of action of these two miRNAs on BCL/MYC expression. Hsa-miR-150p is nodular-specifically overexpressed, and its target ZEB1 was significantly downregulated in nodular SGC suggesting a tumour suppressor role. Invasive pagetoid subtype demonstrated specific overexpression of hsa-miR-205 and downregulation of hsa-miR-199a. Correspondingly, miRNA gene targets, EZH2 (by hsa-miR-205) and CD44 (by hsa-miR-199a), were both overexpressed in pagetoid SGC. CD44 has been identified as a potential cancer stem cell marker in head and neck squamous cell carcinoma and its overexpression in pagetoid cells represents a novel treatment target. Aberrant miRNAs and their gene targets have been identified in both SGC subtypes, paving the way for better molecular understanding of these tumours and identifying new treatment targets.

show abstract

“…Hyperactivation of MEK5 in estrogen receptor positive (ER + ) breast cancer cells enhanced estrogen-independent tumorigenesis ( 10 ). Furthermore, ERK5 is more highly expressed in breast cancer cells and tumor tissue compared to normal breast cells and tissue ( 11 ), and has elevated expression in the more clinically aggressive breast cancer subtype, triple negative breast cancer (TNBC), compared to hormone receptor positive breast cancers ( 10 – 12 ).…”

Section: Introductionmentioning

confidence: 99%